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The incidence of symptomatic venous lesions has
increased significantly during the last decade.
Patients with end-stage renal disease (ESRD) and
arteriovenous fistula (AVF) are most frequently
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Purpose: The clinical success and patency of central and peripheral venous stents in
patients with symptomatic venous obstruction (SVO) were assessed.
Methods: The records of patients with SVO treated with venous stents from 1992 to
1999 were reviewed. Demographic and procedural variables were analyzed to determine
their effect on clinical success, primary patency, and secondary patency. Patency was
determined by means of a follow-up duplex scan or venogram.
Results: Forty central venous (CV) and 14 peripheral venous (PV) obstructions were
treated in 49 patients. Sixty-five stents were placed (50 CV and 15 PV), 54 in previously
unstented lesions and 11 in previously stented lesions. Causes of CV lesions included
catheter placement (82%), tumor compression (6%), arteriovenous fistula (AVF) and no
prior catheter (2%), and other (10%). All PV lesions resulted from complications of dial-
ysis. Indications for CV stents included limb edema (46%), AVF malfunction (30%),
both limb edema and AVF malfunction (14%), and other (10%). PV stent indications
were AVF malfunction (86%) and limb edema (14%). Thirteen CV stents indicated to
treat tumor compression (three cases), May-Thurner syndrome (one case), deep venous
thrombosis (three cases), superior vena cava syndrome (one case), and lower-extremity
catheter-related lesions (five cases) were excluded from the analysis of clinical outcome.
Fifty-two stents (37 CV and 15 PV) were included in the analysis of clinical outcome.
All CV lesions included in the analysis were complications of prolonged catheterization.
Eighty-nine percent of patients had end-stage renal disease and an AVF. Complications
developed in 26% of patients with PV stents and in no patients with CV stents (P <
.002). The mean follow-up period was 16 months. Sixty-two percent of patients
required a reintervention for recurrent SVO. Only 32% of the interventions resulted in
sustained symptomatic improvement. For CV stents, the primary patency rate was 85%,
27%, and 9% at 3, 12, and 24 months, respectively; the secondary patency rate was 91%,
71%, and 39% at 3, 12, and 24 months, respectively; and the clinical success rate was
94%, 94%, and 79%, at 3, 12, and 24 months, respectively. For PV stents, the primary
patency rate was 73%, 17% and 17% at 3, 12, and 24 months, respectively; the secondary
patency rate was 80%, 56%, and 35% at 3, 12, and 24 months, respectively; and the clin-
ical success rate was 92%, 75%, and 42% at 3, 12 and 24 months, respectively. 
Conclusion: Stents provide a temporary benefit in most patients with central or periph-
eral upper-extremity SVO. Regular follow-up and reinterventions are required to main-
tain patency and achieve long-term clinical success. Stents used for CV lesions have high-
er clinical success rates than stents used for PV lesions. Patients with a reasonable life
expectancy or who are unable to return for subsequent procedures should be considered
for undergoing alternative therapy. (J Vasc Surg 2000;32:760-9.)
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affected, reflecting the more frequent use of long-
term indwelling catheters in this population. It is esti-
mated that a venous stenosis will eventually develop
in as many as 40% of patients who undergo a subcla-
vian or brachiocephalic vein catheterization.1 The
pathophysiology is not completely understood, but
probably involves neointimal hyperplasia from repet-
itive and prolonged trauma associated with an abnor-
mally high-flow state.2 As opposed to patients with
arterial disease, these patients are usually asymptom-
atic. However, when an ipsilateral arteriovenous
shunt is placed, venous hypertension may be mani-
fested by arm swelling, pain, or access failure.
The optimal treatment of symptomatic venous
obstruction (SVO) is still controversial. Ligation of the
AVF with the creation of a new access site will usually
provide symptomatic improvement. However, as the
life expectancy of patients with ESRD increases, addi-
tional access sites may no longer be available. For this
reason, the general recommendation has been to pre-
serve each shunt for use as long as possible.
Several approaches have been used to correct
venous lesions, including surgical repair and
endovascular procedures. Operative reconstruction
has been found to have a primary patency rate of
80% to 85% at 1 year in patients with central venous
stenoses.3-9 Most studies on endovascular proce-
dures have reported primary patency rates from 10%
to 30% at 1 year.10-14 However, many authors argue
that the endovascular treatment is less invasive than
and can achieve patency and clinical success rates
similar to those of operative repair. The current
study was undertaken to determine the clinical suc-
cess (symptomatic improvement) and patency rates
of central and peripheral venous stents in patients
with SVO. It reflects a 7-year experience with stent-
ing of 65 symptomatic venous lesions.
METHODS
Patient population. The records of all patients
who underwent primary (first) or secondary (subse-
quent) placement of endoluminal stents for treat-
ment of SVO at three university-affiliated teaching
hospitals from 1992 to 1999 were reviewed.
Symptoms included limb swelling, pain, venous
hypertension, or low flow that resulted in inade-
quate hemodialysis. Ineffective dialysis was deter-
mined by means of the presence of progressively
increasing venous pressures (> 160 mm Hg), flow
rates less than 225 mL/min, or AVF thrombosis.
Patients were divided into two groups, central
and peripheral (defined as a lesion distal to the sub-
clavian vein), for analysis of variables and clinical
outcome. For each patient, medical and demograph-
ic variables, endovascular history, etiology of venous
lesion, and indication for stent placement were
recorded. In addition, venogram findings (location,
extension, and thrombosis) and procedural variables
were noted.
Endovascular procedure and criteria for suc-
cess. Clinical outcomes were assessed with the cal-
culation of the clinical success, primary patency, and
secondary patency rates. Clinical success was evalu-
ated by means of symptom assessment, dividing
patients into one of four groups: cured, better, same,
or worse. The procedure was considered to be clini-
cally successful when the patient reported improved
symptoms (cured or better). Failure was defined as
the lack of symptom improvement, the inability to
correct the venous lesion with a percutaneous pro-
cedure, or the need for operative repair (bypass
grafting, thrombectomy, revision, or ligation). The
stent was defined as patent when no stenosis or a
stenosis of less than 50% was demonstrated by means
of an objective examination (venogram or duplex
scan). Primary patency was defined as uninterrupted
patency, and secondary patency was defined as a
recurrent lesion successfully treated percutaneously
(thrombolysis, thrombectomy, or angioplasty
[PTVA]). Primary patency was lost when the patient
required bypass grafting surgery, revision, or sec-
ondary stenting or when a percutaneous interven-
tion resulted in no improvement in the degree of
stenosis (residual lesion > 50% stenosis). Patients
were routinely restudied at intervals of 4 to 6
months during the first and second year after stent
placement. Patients then usually underwent a yearly
venogram, starting in the third year. Eighty-eight
percent of the patients completed the full follow-up
protocol of postoperative examinations. The most
recent venogram and/or duplex study was used to
determine whether the vein was patent (< 50%
stenosis), stenotic (> 50% stenosis), or occluded.
The number of procedures per month before and
after stenting was used to create a procedure index.
Data analysis. Data were analyzed in accordance
with the suggested standards on reporting results for
endovascular procedures.15 Differences between
means were tested by applying the Student t test or
Mann-Whitney test for nonparametric variables. For
analysis of categorical variables, the χ2 test and
Fisher exact test were used. Clinical success, primary
patency, and secondary patency curves were com-
pared by applying the log-rank test for life table
analysis. A P value less than .05 was used to deter-
mine statistical significance.
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RESULTS
Patient population
Forty-nine patients underwent placement of 65
stents for treatment of 54 symptomatic venous lesions.
In total, 50 stents were placed in central venous (CV)
and 15 in peripheral venous (PV) lesions (Fig 1). Of the
49 patients, 26 were men (53%) and 23 were women
(47%). The age range of patients was 4 to 89 years
(mean age, 50 years). Most patients had upper-extrem-
ity venous hypertension (83%), most often associated
with ESRD/AVF (79%) and earlier catheterization
(69%). To make the study population more homoge-
neous, we excluded CV lesions that resulted from a
variety of other conditions. These included 13 CV
stents indicated to treat tumor compression (3), May-
Thurner syndrome (1), deep venous thrombosis
(DVT; 3), mediastinal fibrosis (1), and catheter-related
iliac thrombosis (5). These were excluded from the
analysis of clinical outcome. Most of these patients had
lesions in the iliac vein (eight patients) or inferior vena
cava (three patients). Therefore, 52 CV stents and 15
PV stents were included in the data analysis. In the CV
stent group (n = 37), there were 27 primary stents and
10 secondary stents; in the PV group there was only
one secondary stent. Table I describes demographic
and medical variables in our patient population.
Previous interventions
Most procedures (66%) were preceded by other
percutaneous radiologic interventions. The number
of interventions ranged from 1 to 11 and was similar
in patients with PV lesions (mean interventions, 2.3)
and CV lesions (mean interventions, 1.78). However,
when secondary stents were excluded, the number of
previous interventions was significantly higher in
patients with PV lesions (2.3) than in patients with
CV lesions (1.1; P < .001). Percutaneous interven-
tions included PTVA in 38 procedures, thrombolysis
in 18 procedures, and previous stent placement in 11
procedures. Ten patients required 11 secondary stent
procedures for treatment of 10 CV and one PV recur-
rent intrastent stenosis (Fig 1).
Endovascular procedure
In our institution, venous stents were usually indi-
cated when the results of PTVA were unsatisfactory
(early lesion recurrence or residual stenosis > 50%).
The type of stent was based on product availability and
physician preference. All procedures were performed
in the radiology suite, and most were done on an out-
patient basis. Patients received systemic intravenous
heparin (3000-5000 units). Venous access was
through an AVF in 28 cases (43%). Catheterization
from the femoral venous approach was used in 25 pro-
cedures (38%), usually for patients with small-caliber,
tortuous, or angulated peripheral upper-extremity
veins, which could not be accessed through the AVF.
Other vessels, such as the basilic, cephalic, or internal
jugular vein, were accessed on 12 occasions (12%).
A diagnostic venogram was undertaken in all
cases as a means of identifying venous pathology
(location, extension, and thrombosis associated
with the venous lesion; Table II). Venous throm-
bosis was treated with 250,000 to 500,000 units
of urokinase. Flexible, self-expanding stents were
used preferentially, because they adapt well to
curved lesions and resist recoil associated with CV
Fig 1. Distribution of primary and secondary stent procedures in 49 patients.
JOURNAL OF VASCULAR SURGERY
Volume 32, Number 4 Oderich et al 763
lesions. Wallstents (Schneider, Minneapolis, Minn)
were used in 60 procedures (48 CV and 12 PV
stents). Palmaz (P308M, Johnson & Johnson
Interventional Systems, Warren, NJ) stainless steel
stents were used in three patients with PV lesions.
One patient with a SVC stenosis was treated with
a Gianturco stent (Cook, Bloomington, Ind), and
one patient was treated with an AVE stent
(Medtronic, Minneapolis, Minn).
There were no procedural complications related to
the puncture site (hematoma, seroma, and infection).
PV interventions resulted in a higher complication rate
than CV interventions (4 of 15 vs 0 of 50; P < .05). A
venous dissection developed in three patients (two
basilic and one cephalic), and rupture of a cephalic vein
developed in one patient during balloon dilation. One
patient had a peripheral stent indicated to treat a
pseudoaneurysm caused by angioplasty. No patient
had stent migration and kinking on follow-up
venograms. Intrastent stenoses most often occurred in
the distal aspect of central stents.
Pathology
Forty-nine percent (18 of 37) of the CV stents
were located in the subclavian vein, 30% (11 of 37)
were located in the innominate, and 5% (2 of 37) were
located in the SVC (Table II). Six patients had com-
bined lesions (innominate/subclavian in four, innom-
inate/internal jugular/SVC in one, and innomi-
nate/SVC in one). There were 10 recurrent intrastent
stenoses, seven in the subclavian vein, two in the
innominate vein, and one in the innominate/subcla-
vian junction. In 30% (11 of 37) of the CV and 53%
(8 of 15) of the PV lesions, there was associated
thrombosis that was successfully treated with uroki-
nase. The incidence of CV thrombosis was similar in
primary (33%) and secondary stents (20%; P < .05).
The mean length of the stented lesion, as measured by
means of the initial venogram, was 6.4 cm for CV and
4.6 cm for PV lesions (P < .05). Most patients (32 of
37) required a single stent to cover the area of steno-
sis. Patients with combined lesions required three
stents in two cases (three vessel lesions) and two stents
in three cases (innominate and subclavian lesions).
There were no procedural complications in these
patients. Peripheral lesions occurred in the venous out-
flow of an AVF in all cases and were distributed in the
basilic (4 of 15), cephalic (7 of 15), and brachial veins
(3 of 15), with one case of venous anastomotic
pseudoaneurysm (1 of 15).
Clinical outcome
Central lesions. For CV lesions, the period of follow-
up ranged from 1 to 64 months, with a mean of 16
months (Table III). Initial clinical success was obtained
in 89% of procedures (33 of 37). Four stents resulted
in no symptomatic improvement (11%). Three patients
had subclavian lesions associated with a malfunctioning
AVF. These patients had residual symptoms after stent-
ing: One patient rethrombosed the AVF, and two
patients underwent surgical revision because of persis-
tent venous hypertension during hemodialysis. Follow-
up venograms were obtained in all three patients, and a
recurrent larger-than-50% stenosis was confirmed. A
final patient with a SVC lesion had limb swelling, which
persisted after stent placement, but it resolved with
operative reconstruction. No patient reported worsen-
ing symptoms after the stent placement.
Eighty-six percent of the CV stents were fol-
lowed with at least one venogram, duplex scan, or
both. The last examination was obtained on average
12.6 months after the initial procedure, with a mean
of 3.68 venograms and 0.43 duplex scans per
Fig 2. Clinical success (circles), secondary patency (trian-
gles), and primary patency (squares) curves for all central
(A) and peripheral (B) venous lesions. A, For central
venous stents, secondary patency and clinical success rates
were significantly higher than the primary patency rate (P
< .05). B, For peripheral venous stents, differences were
not statistically significant. Clinical success was higher for
central stents with the log-rank test (P < .05).
A
B
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patient. The treated lesion was patent in 45% of
patients (14 of 37), stenosed in 32% of patients (10
of 37), and thrombosed in 23% of patients (7 of 37).
Thirty-five percent of the interventions (13 of 37)
resulted in sustained symptomatic improvement,
defined as clinical improvement without the need for
reintervention. The procedure index (defined as the
number of interventions per month) fell from 0.48
(before stent placement) to 0.18 procedures per
month after stent placement (P < .05).
The clinical success, primary patency, and sec-
ondary patency rates for all CV stents is described in
Tables IV, V, and VI, respectively (Fig 2, A). Two
patients with patent stents died of unrelated causes
(gastrointestinal bleeding and myocardial infarction)
during follow-up. Patients with central lesions were
further divided for analysis of clinical outcome
according to the indication (primary and secondary)
and location (subclavian, innominate, SVC, and com-
bined lesions) of the stent procedure. For primary and
secondary CV stents, clinical success (93% vs 100%,
respectively), primary patency (22% vs 22%), and sec-
ondary patency (72% vs 59%) rates were not signifi-
cantly different at the 12-month follow-up examina-
tion (Fig 3, A, B, and C). Patency and clinical success
rates at 12 months were also similar for stents placed
Fig 3. Clinical success (A), secondary patency (B), and
primary patency (C) curves for primary (circles) and sec-
ondary (triangles) central stents. The clinical outcome
did not differ for primary versus secondary stented lesions
(P > .05).
Fig 4. Clinical success (A), secondary patency (B), and
primary patency (C) curves for subclavian (circles), innom-
inate (triangles), and combined (squares) stented venous
lesions. The clinical outcome did not differ for central
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in the subclavian, innominate, and combined lesions
(Fig 4, A, B, and C). Two stents placed in the SVC
were excluded from this analysis. One stent required
a venous bypass graft 1 month after stent placement,
and a second stent required a reintervention (PTVA)
within 1 month after primary stenting, remaining
patent for 31 months thereafter. Overall, patency rates
were higher for innominate lesions than subclavian
lesions. The lack of statistical significance may repre-
sent a type-II error, because the number of innomi-
nate lesions was relatively small in each group.
Peripheral lesions. For PV stents, the clinical
success rate was 92% at 3 months, 75% at 12
months, and 42% at 24 months. The primary paten-
cy rate was 73%, 17%, and 17% at 3, 12, and 24
months, respectively, and the secondary patency rate
was 80%, 56%, and 35% at 3, 12, and 24 months,
respectively (Fig 2, B). There was a tendency toward
better secondary patency rates for CV stents than
PV stents; this was not statistically significant (P >
.05). However, CV stents had a higher clinical suc-
cess rate than peripheral stents (P < .05).
Table I. Demographic and medical variables in patients undergoing stent placement
Variable CV stent (n = 50) PV stent (n = 15) Total (n = 65)
Age (years; mean ± SD) 48 ± 22 58 ± 17 50 ± 21
Sex (male: female) 24:26 8:7 32:33
Cause*
AVF-related/catheter-related 36 (72%) 4 (27%) 40 (61%)
Catheter-related alone 5 (10%) 0 5 (8%)
AVF-related alone 1 (2%) 11 (73%) 12 (18%)
Tumor compression 3 (6%) 0 3 (5%)
Other 5 (10%) 0 5 (8%)
Previous intervention 30 (60%) 13 (86%) 43 (66%)
No. of interventions (mean) 1.8† 2.3† 1.9
Indication
Limb swelling 23 (46%) 0 23 (35%)
AVF malfunction 15 (30%) 13 (86%) 28 (43%)
Both 7 (14%) 0 7 (11%)
Other‡ 5 (10%) 2 (14%) 7 (11%)
*Eighty-nine percent of patients with CV lesions that were included in the analysis had end-stage renal disease/AVF (33 of 37 patients),
and all patients had a history of catheterization. 
†P value < .05.
‡For CV lesions, other causes included facial swelling and headache (4) and combination of arm swelling/pain and AVF malfunction
(1). For PV lesions, one patient had arm pain, and one patient had a pseudoaneurysm caused by previous angioplasty.
AVF, Arteriovenous fistula; CV, central venous; PV, peripheral venous.
Table II. Procedural variables in patients with venous lesions associated with catheter use, hemodialysis, or both
Variable CV stent (n = 37) PV stent (n = 15) Total (n = 52)
Location
Subclavian 18 (49%) – 18 (35%)
Innominate 11 (30%) – 11 (21%)
SVC 2 (5%) – 2 (12%)
Combined 6 (16%) – 6 (4%)
Basilic – 4 (27%) 4 (8%)
Cephalic – 7 (47%) 7 (13%)
Brachial – 3 (20%) 3 (6%)
Venous anastomosis – 1 (6%) 1 (2%)
Central vein thrombosis 19 (38%) 0 19 (37%)
Thrombolysis 19 (38%) 8 (53%) 27 (42%)
Extension of occlusion/stenosis
Central-affected and AVF-affected 12 (32%) 0 12 (23%)
Central-affected and AVF patent 20 (54%) 0 20 (38%)
Central-affected and no AVF 5 (14%) 0 5 (10%)
AVF-affected 0 15 (100%) 15 (29%)
AVF, Arteriovenous fistula; CV, central venous; PV, peripheral venous; SVC, superior vena cava.
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DISCUSSION
The advances in endovascular surgery have sig-
nificantly contributed to the treatment of patients
with symptomatic venous lesions. New stents were
designed to incorporate visibility, flexibility, and
expandability, permitting the treatment of the most
complex venous lesion through endovascular means.
Potential advantages of this approach include its less
invasive nature, safety, ability to be done on an out-
patient basis, better preservation of native veins,
and, most important, its association with greater
patient satisfaction and less discomfort. However,
no study has previously documented the long-term
clinical success rates for endovascular stenting.
Most of our patients had upper-extremity cen-
tral venous lesions associated with ESRD, AVF,
and a history of prior catheterization. In these
patients, no randomized study that adequately
compares surgery with an endovascular approach
exists. Surgery is usually regarded as a major under-
taking and is reserved for patients unable to be
effectively treated with angioplasty, stenting, or
both. Options for operative reconstructions
include internal jugular (IJ)-to-subclavian vein
transposition (subclavian lesions not involving the
IJ vein), subclavian/axillary-to-IJ vein bypass graft-
ing (subclavian lesions), and subclavian-to-SVC/
right atrial bypass grafting (innominate and/or
SVC lesions). These techniques frequently require
resection of the clavicle for mobilization of the IJ
vein down to the innominate vein or a medial 
sternotomy to access the distal SVC and/or right
atrium, which adds to the morbidity and risk asso-
ciated with a general anesthetic.
Table III. Follow-up of patients with venous lesions associated with catheter use, hemodialysis, or both
Variable CV stent (n = 37) PV stent (n = 15) Total (n = 52)
Symptom assessment
Cured 24 (65%) 10 (67%) 34 (65%)
Better 9 (24%) 5 (33%) 14 (27%)
Same 4 (11%) 0 4 (8%)
Worse 0 0 0
Clinical success at 1 mo 33 (89%) 15 (100%) 48 (93%)
Symptom-free interval (mean mo) 6.6 4.5 6.0
Reintervention 22 (59%) 10 (67%) 32 (62%)
Procedure index prestent 0.48* 0.51 0.47
Procedure index poststent 0.13* 0.38 0.21
Venogram/duplex scan obtained 31 (86%) 14 (93%) 45 (87%)
Patent 14 (45%)* 1 (7%)* 15 (33%)
Stenosed 10 (32%) 4 (29%) 14 (31%)
Occluded 7 (23%)* 9 (64%)* 16 (36%)
Follow-up period (mean mo) 15.8 13.2 15.1
AVF life (after stenting, in mo) 12.6 12.8 12.7
Procedure index was defined as the number of interventions per month before (prestent) and after (poststent) stent placement.
*P < .05.
AVF, Arteriovenous fistula; CV, central venous; PV, peripheral venous.
Table IV. Clinical success rates in patients with upper-extremity central venous lesions associated with
catheter use, hemodialysis, or both
No. withdrawn patent because of
No. of stents No. of Loss to Interval Cumulative
Interval (mo) at-risk at start failed stents Duration follow-up Death patency rate patency (%) SE (%)
0 to 1 37 2 3 1 0 0.94 100 0.00
1 to 3 31 0 1 0 1 1.00 94 4.15
3 to 6 29 0 1 0 0 1.00 94 4.29
6 to 9 28 0 2 2 1 1.00 94 4.37
9 to 12 23 0 3 0 0 1.00 94 4.82
12 to 15 20 0 3 1 0 1.00 94 5.17
15 to 18 16 2 2 1 0 0.85 94 5.78
18 to 21 11 0 1 2 0 1.00 79 10.85
21 to 24 8 0 1 1 0 1.00 79 12.73
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In our series, endovascular stenting of central
venous lesions was safe and offered a clinical success
rate of 79% at 24 months of follow-up. The primary
patency rate was limited (22% in 12 months), and
most of our patients (60%) required a reintervention
to maintain long-term symptomatic improvement.
Most series, however, have found that surgery pro-
vides superior primary patency (80% at 12 months).3-
9 Bhatia et al3 retrospectively reviewed 26 patients
with subclavian and innominate venous lesions who
were treated with either venous bypass grafting or
stenting. The primary patency rate at 12 months in
the surgical group was 83%; the long-term patency
rate was not reported for stents. The percentage of
patients who were symptom free at 6 and 12 months
was similar in both groups. This was also confirmed
by Sottiarai et al.4 Wisselink et al5 compared operative
reconstruction and angioplasty for central venous
lesions and found that primary symptomatic relief at 1
year was 88% in the surgical group and 36% in the
angioplasty group; at 2 years, 71% of the surgical
patients and none of the endovascular group were
asymptomatic. However, with reintervention, results
of angioplasty approached those achieved with opera-
tive reconstruction. Excellent long-term results were
also shown by El-Sabrout and Duncan8 in patients
who underwent right atrial bypass grafting for central
venous lesions. There was no mortality related to the
procedure. However, morbidity was significant (30%),
reinforcing the general recommendation to reserve
operative reconstruction for the occasional low-risk
patient in whom access sites are exhausted and in
whom repeated endovascular procedures have failed.
Angioplasty alone may represent a reasonable
option for the treatment of central venous lesions.
Stents are thought to add a beneficial effect to
angioplasty by limiting the elastic recoil present in
compliant veins, excluding damaged and dissected
intravascular tissue, and acting as an intravascular
support to counteract extrinsic compression. This is
especially relevant for central venous lesions,
described to have high elastic recoil and poor results
with PTVA alone. Davidson et al16 demonstrated
that central, as opposed to peripheral, lesions fre-
Table V. Primary patency rates in patients with upper-extremity central venous lesions associated with
catheter use, hemodialysis, or both
No. withdrawn patent because of
No. of stents No. of Loss to Interval Cumulative 
Interval (mo) at-risk at start failed stents Duration follow-up Death patency rate patency (%) SE (%)
0 to 1 37 5 3 0 0 0.85 100 0.00
1 to 3 29 3 1 0 1 0.89 85 6.07
3 to 6 24 11 0 0 0 0.54 76 7.60
6 to 9 13 4 1 0 1 0.65 41 8.76
9 to 12 7 2 1 0 0 0.67 27 8.68
12 to 15 4 1 0 0 0 0.75 18 8.11
15 to 18 3 1 0 0 0 0.67 13 7.21
18 to 21 2 0 0 0 0 1.00 9 6.04
21 to 24 2 1 0 0 0 0.50 9 6.04
Table VI. Secondary patency rates in patients with upper-extremity central venous lesions associated with
catheter use, hemodialysis, or both
No. withdrawn patent because of
No. of stents No. of Loss to Interval Cumulative 
Interval (mo) at-risk at start failed stents Duration follow-up Death patency rate patency (%) SE (%)
0 to 1 37 3 3 0 0 0.91 100 0.00
1 to 3 31 2 1 0 1 0.93 91 4.86
3 to 6 27 2 0 0 0 0.93 85 6.34
6 to 9 25 2 1 2 1 0.91 79 7.26
9 to 12 19 3 2 0 0 0.82 71 8.76
12 to 15 14 2 1 0 0 0.85 59 10.09
15 to 18 11 2 1 1 0 0.78 50 10.63
18 to 21 7 0 1 0 0 1.00 39 11.45
21 to 24 6 1 0 0 0 0.83 39 12.37
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quently had vessel stretch followed by more than
50% elastic recoil. Kovalic et al17 confirmed that
patients with central lesions and marked elastic recoil
had poor patency rates with angioplasty alone
(mean, 2.9 months), when compared with angio-
plasty and stenting (mean, 8.6 months). Quinn et
al10 reported on the preliminary results of an ongo-
ing prospective trial comparing PTVA with stenting.
Forty-seven patients were treated with PTVA alone,
and 40 patients underwent PTVA with stenting;
68% of patients had a peripheral venous lesion asso-
ciated with a dialysis shunt. The primary patency rate
for angioplasty at 12 months was 10%, and for
stents, the primary patency rate was 21%. The sec-
ondary patency rates were 80% and 64%, respective-
ly. For central lesions, the primary patency rate was
11% in both the angioplasty and the stent group. In
other series, the primary patency rate ranged from
12% to 36% with angioplasty alone.11-14 Stent place-
ment increased the primary patency rate on average
by 10% at 12 months (20% to 45%).10-14 Stents also
seem to add the benefit of reducing the number of
interventions in patients treated with an endovascu-
lar approach. Turmel-Rodrigues et al18 reported a
reduction in the ratio of procedures for restenoses
after stent placement. In our study, patients with
central stents also experienced fewer interventions
per month (procedure index). Whether stenting will
have a positive or negative impact on the economic
cost of the treatment of venous stenoses remains to
be determined.
Peripheral stents represented a smaller group in
our population and were analyzed separately. Their
clinical success rate was lower than that of central
stents (42% and 81% at 24 months). Patency rates
were similar, with a tendency toward lower patency
rates in the peripheral stent group. Most of the
reported series failed to stratify results according to
stent location. Patients with central lesions clearly
represent a distinct population in etiology (catheter-
related instead of AVF-related), presenting symp-
toms (limb swelling instead of AVF malfunction),
and venous hemodynamics. Patients with central
stents are frequently asymptomatic, despite a signifi-
cant stenosis. One possible explanation is that collat-
erals develop in these patients with time, keeping
their pressures within normal limits. Sullivan et al19
demonstrated a nonlinear increase in venous pres-
sures with increasing severity of the degree of steno-
sis, suggesting that collateral flow may increase as
stenoses progress. For peripheral stents, however,
more severe stenoses tended to produce higher
increases in pressure levels, presumably because of
the fewer distensible collaterals to accommodate
pressure changes. Collateral flow may explain why
discrepancies between symptom improvement and
patency are more accentuated for central lesions
than for peripheral lesions.
The clinical outcome was similar for stents placed
in different locations and for primary and secondary
stents. However, our study population was too small
to make conclusions about population subsets. At 24
months of follow-up, for example, there were only six
patients at risk in the subclavian vein group and none
in the innominate vein group. The lack of statistical
difference may represent a type-II error. To avoid fur-
ther confusion in the analysis of clinical outcome, we
opted to exclude lesions with uncommon etiologies
and lesions known to have excellent durability after
stent placement. Patients with lower-extremity venous
hypertension often had venous lesions associated with
primary DVT, tumor compression, and other causes.
Mickley et al20 reported excellent results of stenting
of iliac venous lesions caused by DVT; their primary
and secondary patency rates were 71% and 82%,
respectively, at 24 months. Patients with tumor-relat-
ed venous hypertension have a limited life expectancy,
and stenting usually offers excellent palliation.21 It
would be difficult to compare these patients (tumor
compression, May Thurner syndrome, primary DVT)
with patients who have catheter-related and AVF-
related venous lesions.
Our study was a retrospective review of patients
selected from all patients who underwent endovascu-
lar treatment in two academic institutions. No objec-
tive criteria were used to determine which patients
would undergo stent placement. In general, patients
with early restenosis or patients with an unsatisfacto-
ry result after angioplasty were selected for stent
placement. The analysis of clinical outcome was
restricted to a very specific population with CV and
PV lesions associated with prolonged catheterization,
hemodialysis, or both. Therefore, generalizations to
stent procedures used for other lesions should be
made carefully. Accurate comparisons between our
results and those reported in the literature are diffi-
cult because of the variations in methods, patency
definition, indication, population studied (mixing
central and peripheral lesions), small number of
patients, limited follow-up period, and the recogni-
tion that most studies are retrospective.
CONCLUSION
Stenting of central and peripheral lesions offers
limited primary patency, and recurrent stenosis will
develop in most patients (62%) within 1 year. To
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achieve a clinical and radiological result similar to
those reported for the surgical treatment, most
patients will require multiple interventions. Our
study found that the symptom-free period between
reinterventions is prolonged after stent placement.
The clinical outcome for central lesions is superior to
that for peripheral lesions. Therefore, the decision of
whether surgery or stenting is most suitable for an
individual patient requires consideration of the mor-
bidity associated with surgery and the higher recur-
rence rate of the endovascular approach. Angioplasty
and stenting are safe and should be strongly consid-
ered in patients with severe comorbidities, high oper-
ative risk, or a limited number of access sites.
However, surgery may represent a superior option
for patients who are young and otherwise healthy,
have a reasonable life expectancy, and are unable to
return for subsequent procedures. Definitive recom-
mendations regarding the ideal treatment of sympto-
matic venous lesions will require the collaboration of
large volume institutions to implement a prospective
trial comparing surgery and endovascular procedures
in the treatment of symptomatic venous lesions.
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